Wellington Management Group
SYRS

Wellington Management Group’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Wellington Management Group’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-103,086
Closed -$13.4M – 2332
2018
Q1 		$13.4M Buy
103,086
+3,408
+3% +$373K ﹤0.01% 1193
2017
Q4 		$9.7M Buy
99,678
+82
+0.1% +$11K ﹤0.01% 1283
2017
Q3 		$14.7M Buy
99,596
+87
+0.1% +$16.4K ﹤0.01% 1173
2017
Q2 		$16M Buy
+99,509
New +$15.6M ﹤0.01% 1103

Other funds holding SYRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group's SYRS Position: Q2 2018 in Review

Wellington Management Group sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2018, closing a stake of 103,086 shares — an estimated $13.4M sold.

Wellington Management Group first reported a position in SYRS in Q2 2017 and held it in 4 quarters. The position peaked at $16M in Q2 2017. 76 funds tracked by Wall St. Rank hold SYRS as of Q2 2018.

  • Wellington Management Group reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • Wellington Management Group sold 103,086 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2018, an estimated $13.4M.
  • Wellington Management Group first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2017 and held it in 4 quarters.
  • Wellington Management Group's Syros Pharmaceuticals, Inc. Common Stock position peaked at $16M in Q2 2017.
  • 76 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2018.

Based on Wellington Management Group's 13F filing for Q2 2018, filed 14 Aug 2018.